#Innovent Biologics

Last 24h 📈 Bullish 📈1

Last 7 Days 📈 Bullish 📈1

Last 30 Days 📈 Bullish 📈1

Release 📈 Stocks

Innovent Biologics Expands Phase 3 MarsLight-11 Study for NSCLC Treatment

September 28, 2026 (just now)

Innovent Biologics broadens the scope of its Phase 3 MarsLight-11 study, targeting a wider patient population for its IBI363/TAK-928 oncology candidate to…

01801.HK

🌍 ASIA Read More →